Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Alkeus Pharmaceuticals

Alkeus Pharmaceuticals Presents Gildeuretinol Data During the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting May 4-8, 2025
From Alkeus Pharmaceuticals
Via GlobeNewswire
Alkeus Pharmaceuticals Announces Presentations of Gildeuretinol Data During the Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting May 4-8, 2025
From Alkeus Pharmaceuticals
Via GlobeNewswire
Alkeus Pharmaceuticals Announces Establishment of Scientific Advisory Board
From Alkeus Pharmaceuticals
Via GlobeNewswire
Alkeus Pharmaceuticals Announces Two Presentations of Oral Gildeuretinol Data During the 48th Annual Meeting of the Macula Society Being Held February 12-15, 2025
From Alkeus Pharmaceuticals
Via GlobeNewswire
Alkeus Pharmaceuticals Announces New Positive Interim TEASE-3 Study Results Showing Gildeuretinol Prevented Disease Progression in Early-Stage Stargardt Patients
From Alkeus Pharmaceuticals
Via GlobeNewswire
Alkeus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Alkeus Pharmaceuticals
Via GlobeNewswire
Alkeus Pharmaceuticals Announces Positive Gildeuretinol Data Will Be Presented During the 12th International FLORetina ICOOR Congress December 5–8 in Florence, Italy
From Alkeus Pharmaceuticals
Via GlobeNewswire
Alkeus Pharmaceuticals Receives FDA Rare Pediatric Disease and Fast Track Designations for Gildeuretinol as a Treatment for Stargardt Disease
From Alkeus Pharmaceuticals
Via GlobeNewswire
Alkeus Pharmaceuticals Appoints David Arkowitz as Chief Financial Officer
From Alkeus Pharmaceuticals
Via GlobeNewswire
Topline Results from Alkeus Pharmaceuticals’ Study of Oral Gildeuretinol Demonstrate Significant Trend in Slowing GA Progression and Visual Function Improvement
From Alkeus Pharmaceuticals
Via GlobeNewswire
Alkeus Pharmaceuticals Announces Data Presentations at the American Academy of Ophthalmology (AAO) 2024 Annual Meeting, October 18-21 in Chicago
From Alkeus Pharmaceuticals
Via GlobeNewswire
Alkeus Pharmaceuticals Announces Results from the SAGA Study of Oral Gildeuretinol in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
From Alkeus Pharmaceuticals
Via GlobeNewswire
Alkeus Pharmaceuticals Announces Presentation of a TEASE-3 Study Update Showing Progression Stalled in Early-Stage Stargardt Disease Patients Treated with Gildeuretinol
From Alkeus Pharmaceuticals
Via GlobeNewswire
Alkeus Pharmaceuticals Appoints Tamara Dillon as Chief Human Resources Officer
From Alkeus Pharmaceuticals
Via GlobeNewswire
Accomplished Biotech Leader Michel Dahan Joins Alkeus as President and CEO
From Alkeus Pharmaceuticals
Via GlobeNewswire
Alkeus Pharmaceuticals Appoints Eric L. Trachtenberg as Chief Legal Officer
From Alkeus Pharmaceuticals
Via GlobeNewswire
Alkeus Pharmaceuticals Announces Positive Interim Results Demonstrating No Signs of Disease Progression in Early-Stage Stargardt Disease Patients Treated with Gildeuretinol
From Alkeus Pharmaceuticals
Via GlobeNewswire
Alkeus Pharmaceuticals Announces Presentation of Positive Gildeuretinol Data in Early-Stage Stargardt Patients During the ARVO 2024 Annual Meeting May 5-9
From Alkeus Pharmaceuticals
Via GlobeNewswire
Alkeus Pharmaceuticals Appoints Seemi Khan, M.D., Chief Medical Officer
From Alkeus Pharmaceuticals
Via GlobeNewswire
Alkeus Pharmaceuticals Presents Positive Interim Data Showing Gildeuretinol Halted Stargardt Disease Progression
From Alkeus Pharmaceuticals
Via GlobeNewswire
Alkeus Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Jan. 10, 2024
From Alkeus Pharmaceuticals
Via GlobeNewswire
Alkeus Pharmaceuticals Presents Positive Gildeuretinol Trial Results at American Academy of Ophthalmology, Demonstrating Significant Slowing of Retinal Atrophic Lesions in Stargardt Disease
From Alkeus Pharmaceuticals
Via GlobeNewswire
Alkeus Announces $150 Million Series B Financing, Supporting Rapid Registration Path for gildeuretinol (ALK-001) in the Treatment of Stargardt Disease
From Alkeus Pharmaceuticals
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.